Search Results - "Lindert, S."

Optimising primary molecular profiling in non-small cell lung cancer by Schouten, R D, Schouten, I, Schuurbiers, M M F, van der Noort, V, Damhuis, R A M, van der Heijden, E H F M, Burgers, J A, Barlo, N P, van Lindert, A S R, Maas, K W, van den Brand, J J G, Smit, A A J, van Haarst, J M W, van der Maat, B, Schuuring, E, Blaauwgeers, H, Willems, S M, Monkhorst, K, van den Broek, D, van den Heuvel, M M

“…Molecular profiling of NSCLC is essential for optimising treatment decisions, but often incomplete. We assessed the efficacy of protocolised molecular…”
Get full text

Nationwide differences in cytology fixation and processing methods and their impact on interlaboratory variation in PD-L1 positivity by Koomen, Bregje M., de Boer, Mirthe, van Dooijeweert, Carmen, van Lindert, Anne S. R., Deckers, Ivette A. G., Voorham, Quirinus J. M., Willems, Stefan M.

“…Programmed death ligand-1 (PD-L1) immunostaining, which aids clinicians in decision-making on immunotherapy for non-small cell lung cancer (NSCLC) patients, is…”
Get full text

Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition by van Eijs, Mick J. M., Verheijden, Rik J., van der Wees, Stefanie A., Nierkens, Stefan, van Lindert, Anne S. R., Suijkerbuijk, Karijn P. M., van Wijk, Femke

“…Immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape of advanced malignancies, but come with a diverse spectrum of immune-related…”
Get full text

Individual treatment effect estimation in the presence of unobserved confounding using proxies: a cohort study in stage III non-small cell lung cancer by van Amsterdam, Wouter A. C., Verhoeff, Joost. J. C., Harlianto, Netanja I., Bartholomeus, Gijs A., Puli, Aahlad Manas, de Jong, Pim A., Leiner, Tim, van Lindert, Anne S. R., Eijkemans, Marinus J. C., Ranganath, Rajesh

“…Randomized Controlled Trials (RCT) are the gold standard for estimating treatment effects but some important situations in cancer care require treatment effect…”
Get full text

Hematologic malignancies following immune checkpoint inhibition for solid tumors by van Eijs, Mick J. M., van der Wagen, Lotte E., Mous, Rogier, Leguit, Roos J., van de Corput, Lisette, van Lindert, Anne S. R., Suelmann, Britt B. M., Kamphuis, Anna M., Nierkens, Stefan, Suijkerbuijk, Karijn P. M.

“…Immune checkpoint inhibition (ICI) can induce durable responses in patients with advanced malignancies. Three cases of hematological neoplasia following ICI…”
Get full text

Open communication between patients and relatives about illness & death in advanced cancer—results of the eQuiPe Study by Haaksman, Michelle, Ham, Laurien, Brom, Linda, Baars, Arnold, van Basten, Jean-Paul, van den Borne, Ben E. E. M., Hendriks, Mathijs P., de Jong, Wouter K., van Laarhoven, Hanneke W. M., van Lindert, Anne S. R., Mandigers, Caroline M. P. W., van der Padt-Pruijsten, Annemieke, Smilde, Tineke J., van Zuylen, Lia C., van Vliet, Liesbeth M., Raijmakers, Natasja J. H.

“…Objective To assess the degree of openness of communication about illness and death between patients with advanced cancer and their relatives during the last…”
Get full text

Non-Small-Cell Lung Cancer Patients with a High Predicted Risk of Irradical Resection: Can Chemoradiotherapy Offer Similar Survival? by van Joolingen, W. Hugo, Rasing, Marnix J. A., Peters, Max, van Lindert, Anne S. R., de Heer, Linda M., Aarts, Mieke J., Verhoeff, Joost J. C., van Rossum, Peter S. N.

“…Purpose Irradical resection of non-small-cell lung cancer (NSCLC) is a detrimental prognostic factor. Recently, Rasing et al. presented an internationally…”
Get full text

ASO Visual Abstract: Non-small Cell Lung Cancer Patients with a High Predicted Risk of Irradical Resection—can Chemoradiotherapy Offer Similar Survival? by van Joolingen, W. Hugo, Rasing, Marnix J. A., Peters, Max, van Lindert, Anne S. R., de Heer, Linda M., Aarts, Mieke J., Verhoeff, Joost J. C., van Rossum, Peter S. N.

Get full text

Treatment decision‐making and the added value of the general practitioner: A qualitative exploration of cancer patients' perspectives by Noteboom, Eveline A., Vervoort, Sigrid C. J. M., May, Anne M., Dorst, Eleonora B. L., Lindert, Anne S. R., Elst, Maarten W., Bijlsma, Rhodé M., Wall, Elsken, Wit, Niek J., Helsper, Charles W.

“…Objective Cancer patients are increasingly involved in decision‐making for cancer treatment. General practitioners' (GPs) support in this process is advocated…”
Get full text

Long-term Local Control and Overall Survival After Radiotherapy in Oligoprogressive Patients During Treatment With Checkpoint Inhibitors by DAMEN, PIM J.J., SUIJKERBUIJK, KARIJN P.M., VAN LINDERT, ANNE S.R., EPPINGA, WIETSE S.C., EL SHAROUNI, SHERIF Y., VERHOEFF, JOOST J.C.

“…Background/Aim: Recent studies described the safety and clinical utility of combined anti-programmed cell death protein-1 (anti-PD1) checkpoint inhibition with…”
Get full text

Cerebrospinal fluid lymphocytosis: a hallmark of neurological complications during checkpoint inhibition by Tonk, Erwin H.J., Snijders, Tom J., Koldenhof, José J., van Lindert, Anne S.R., Suijkerbuijk, Karijn P.M.

Get full text

Association between Genetic Variants and Peripheral Neuropathy in Patients with NSCLC Treated with First-Line Platinum-Based Therapy by de Jong, Corine, Herder, Gerarda J M, van Haarlem, Simone W A, van der Meer, Femke S, van Lindert, Anne S R, Ten Heuvel, Alexandra, Brouwer, Jan, Egberts, Toine C G, Deneer, Vera H M

“…Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, disabling side effect in non-small cell lung cancer (NSCLC) patients treated with…”
Get full text

Prognostic factors for overall survival of stage III non-small cell lung cancer patients on computed tomography: A systematic review and meta-analysis by van Laar, Myra, van Amsterdam, Wouter A.C., van Lindert, Anne S.R., de Jong, Pim A., Verhoeff, Joost J.C.

“…•This review includes data of 144,513 stage III NSCLC patients from 65 studies.•Most studies had medium methodological quality, failing to report one/more…”
Get full text

Ultra-central lung tumors: safety and efficacy of protracted stereotactic body radiotherapy by Lodeweges, Joyce E, van Rossum, Peter S N, Bartels, Marcia M T J, van Lindert, Anne S R, Pomp, Jacqueline, Peters, Max, Verhoeff, Joost J C

“…For patients with early stage or medically inoperable lung cancer, stereotactic body radiotherapy (SBRT) is a general accepted and effective treatment option…”
Get more information

Physical activity and checkpoint inhibition: association with toxicity and survival by Verheijden, Rik J, Cabané Ballester, Anna, Smit, Karel C, van Eijs, Mick J M, Bruijnen, Cheryl P, van Lindert, Anne S R, Suijkerbuijk, Karijn P M, May, Anne M

“…Although animal experiments suggest beneficial effects of physical activity (PA) on antitumor immunity, little is known about the effects of PA on immune…”
Get full text

Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer by Kuijpers, C.C.H.J., Hendriks, L.E.L., Derks, J.L., Dingemans, A-M.C., van Lindert, A.S.R., van den Heuvel, M.M., Damhuis, R.A., Willems, S.M.

“…•NSCLC molecular status was associated with metastatic pattern at diagnosis.•EGFR+ tumors more often bone and pleural metastases than triple-negative.•EGFR+…”
Get full text

Patient-Reported Outcomes During Checkpoint Inhibition: Insight into Symptom Burden in Daily Clinical Practice by Koldenhof, Josephine J., van der Baan, Frederieke H., Verberne, Elisabeth G., Kamphuis, Annemarleen M., Verheijden, Rik J., Tonk, Erwin H., van Lindert, Anne S., van der Stap, Janneke, Teunissen, Saskia C., Witteveen, Petronella O., Suijkerbuijk, Karjin P.

“…While praised for inducing durable anti-tumour responses, immune checkpoint inhibitors (ICI) also cause immune-related adverse events (irAEs) that can vary in…”
Get full text

Considerable interlaboratory variation in PD-L1 positivity in a nationwide cohort of non-small cell lung cancer patients by Koomen, Bregje M., Voorham, Quirinus J.M., Epskamp-Kuijpers, Chantal C.H.J., van Dooijeweert, Carmen, van Lindert, Anne S.R., Deckers, Ivette A.G., Willems, Stefan M.

“…•Considerable variation in PD-L1 positivity exists between pathology laboratories.•Variation is greatest when PD-L1 positivity is determined according to the…”
Get full text

Feasibility and first results of the 'Trials-within-Cohorts' (TwiCs) design in patients undergoing radiotherapy for lung cancer by Tomassen, Mathijs L, Damen, Pim J J, Verkooijen, Helena M, Peters, Max, van der Stap, Janneke, van Lindert, Anne S R, Verhoeff, Joost J C, van Rossum, Peter S N

“…'Trials-within-Cohorts' (TwiCs), previously known as 'cohort multiple randomized controlled trials' is a pragmatic trial design, supporting an efficient and…”
Get more information

Quantification of epicardial and peri-coronary fat using cardiac computed tomography; reproducibility and relation with obesity and metabolic syndrome in patients suspected of coronary artery disease by Gorter, Petra M, van Lindert, Anne S.R, de Vos, Alexander M, Meijs, Matthijs F.L, van der Graaf, Yolanda, Doevendans, Pieter A, Prokop, Mathias, Visseren, Frank L.J

“…Abstract Objective Adipose tissue surrounding coronary arteries may contribute to the development of coronary atherosclerosis given its localisation and…”
Get full text